Compare COMBAT DRUGS with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DECIPHER LABS vs DR. REDDYS LAB - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DECIPHER LABS DR. REDDYS LAB DECIPHER LABS/
DR. REDDYS LAB
 
P/E (TTM) x 4.6 27.6 16.8% View Chart
P/BV x 3.8 4.0 95.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DECIPHER LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    DECIPHER LABS
Mar-21
DR. REDDYS LAB
Mar-21
DECIPHER LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs415,515 0.7%   
Low Rs183,028 0.6%   
Sales per share (Unadj.) Rs55.01,145.4 4.8%  
Earnings per share (Unadj.) Rs1.4114.5 1.2%  
Cash flow per share (Unadj.) Rs2.2188.4 1.2%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs13.61,053.2 1.3%  
Shares outstanding (eoy) m10.10166.30 6.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.53.7 14.4%   
Avg P/E ratio x21.337.3 57.0%  
P/CF ratio (eoy) x13.422.7 59.2%  
Price / Book Value ratio x2.24.1 53.8%  
Dividend payout %021.8 0.0%   
Avg Mkt Cap Rs m298710,289 0.0%   
No. of employees `000NANA-   
Total wages/salary Rs m47336,299 1.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m556190,475 0.3%  
Other income Rs m62,914 0.2%   
Total revenues Rs m562193,389 0.3%   
Gross profit Rs m3538,699 0.1%  
Depreciation Rs m812,288 0.1%   
Interest Rs m12970 1.2%   
Profit before tax Rs m2128,355 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79,319 0.1%   
Profit after tax Rs m1419,036 0.1%  
Gross profit margin %6.320.3 30.9%  
Effective tax rate %34.532.9 105.1%   
Net profit margin %2.510.0 25.3%  
BALANCE SHEET DATA
Current assets Rs m225145,503 0.2%   
Current liabilities Rs m17381,038 0.2%   
Net working cap to sales %9.433.8 27.8%  
Current ratio x1.31.8 72.5%  
Inventory Days Days7761 125.2%  
Debtors Days Days76695 805.6%  
Net fixed assets Rs m161109,979 0.1%   
Share capital Rs m101832 12.1%   
"Free" reserves Rs m36174,319 0.0%   
Net worth Rs m137175,151 0.1%   
Long term debt Rs m676,299 1.1%   
Total assets Rs m387255,482 0.2%  
Interest coverage x2.830.2 9.4%   
Debt to equity ratio x0.50 1,363.8%  
Sales to assets ratio x1.40.7 192.8%   
Return on assets %6.77.8 85.0%  
Return on equity %10.210.9 94.3%  
Return on capital %16.216.2 100.5%  
Exports to sales %051.3 0.0%   
Imports to sales %018.1 0.0%   
Exports (fob) Rs mNA97,699 0.0%   
Imports (cif) Rs mNA34,420 0.0%   
Fx inflow Rs m097,699 0.0%   
Fx outflow Rs m034,420 0.0%   
Net fx Rs m063,279 0.0%   
CASH FLOW
From Operations Rs m1835,703 0.1%  
From Investments Rs m-3-22,660 0.0%  
From Financial Activity Rs m40-298 -13.4%  
Net Cashflow Rs m5512,858 0.4%  

Share Holding

Indian Promoters % 0.0 26.7 -  
Foreign collaborators % 34.2 0.0 -  
Indian inst/Mut Fund % 0.1 49.9 0.1%  
FIIs % 0.0 25.2 -  
ADR/GDR % 0.0 11.2 -  
Free float % 65.8 62.1 106.1%  
Shareholders   42,673 263,803 16.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DECIPHER LABS With:   CIPLA    SUN PHARMA    LUPIN    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

4 Reasons Why Sensex Rallied 1,534 Points Today(0)

Bulls marked a strong comeback today as Indian share markets ended nearly 3% higher. After opening the day higher, equity markets extended gains as the session progressed and ended near the day's high.

Related Views on News

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DECIPHER LABS SHARE PRICE


May 20, 2022 (Close)

TRACK DECIPHER LABS

  • Track your investment in DECIPHER LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DECIPHER LABS 5-YR ANALYSIS

COMPARE DECIPHER LABS WITH

MARKET STATS